Table of contents
Severe asthma phenotypes
Asthma is a disorder of the lower respiratory tract characterized by reversible airflow obstruction and episodic or persistent symptoms of wheezing, dyspnea, and cough.
The cause of asthma is unknown; however, a combination of genetic factors (alterations in ORMDL3, HLAG, IRAKIM, MYB, ADAM33, FLG), epigenetic changes (alterations in DNA methylation, histone modifications, mitochondrial gene silencing) and environmental factors (air pollutants, allergens, respiratory infections) have been implicated.
The estimated prevalence of asthma in the US is 7,400 persons per 100,000 population. The incidence of adult-onset asthma is estimated at 153 cases per 100,000 person-years.
In patients with asthma, exposure to allergens causes airway inflammation, leading to airway obstruction, hyperresponsiveness, and airway remodeling. These changes are associated with the clinical manifestations of to wheezing, coughing, chest tightness, and dyspnea.
Prognosis and risk of recurrence
Patients with asthma have excess all-cause mortality, with a standardized mortality rate estimated at 1.54 in males and 1.91 in females. Patients with frequent exacerbations have an annual loss of lung function approximately 2% greater than predicted.
The following summarized guidelines for the evaluation and management of severe asthma phenotypes are prepared by our editorial team based on guidelines from the National Heart, Lung, and Blood Institute (NHLBI 2020), the Canadian Thoracic Society (CTS 2017), and the European Respiratory Society (ERS/ATS 2014).
1.Screening and diagnosis
Diagnosis: confirm the diagnosis of asthma based on history and objective measures of lung function in patients old enough to reliably undergo pulmonary function tests.
Show 4 more
As per CTS 2017 guidelines:
Obtain total serum IgE level measurement, peripheral eosinophil count, and where available sputum eosinophils and fractional exhaled nitric oxide levels in patients with confirmed severe asthma, in order to characterize the phenotype.
sputum eosinophils may help in identifying responders to anti-IL-5 therapies but not in identifying responders to macrolides
blood eosinophil counts may help to identify patients that will experience fewer exacerbations with anti-IL-5 therapies and omalizumab
insufficient evidence for the use of fractional exhaled nitric oxide to predict response or responders to omalizumab or anti-IL-5 therapies
serum IgE does not predict response to anti-IL-5 therapies or omalizumab
General principles: consider using sputum eosinophil counts, obtained in centers experienced in using this technique, in addition to clinical criteria to guide treatment in adult patients with severe asthma.
Show 2 more
More topics in this section
ICSs and SABAs
ICSs and LABAs
Other biologic agents
Bronchial thermoplasty: as per NHLBI 2020 guidelines, consider offering bronchial thermoplasty in ≥ 18 years old patients with persistent asthma placing a low value on harms (short-term worsening symptoms and unknown long-term side effects) and a high value on potential benefits (improvement in QoL, a small reduction in exacerbations).
Self-management counseling: provide comprehensive self-management asthma education in patients with suspected or confirmed severe asthma, and obtain an evaluation by an asthma specialist.